Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells

Area of Science:

• Oncology
• Pharmacology
• Natural Products Chemistry

Background:

• Cancer stem-like cells drive tumor growth and therapy resistance.
• Estrogen receptor (ER)-negative breast cancer, particularly HER2-positive subtypes, requires novel therapeutic strategies.
• Targeting cancer stem-like cells is crucial for effective breast cancer treatment.

Purpose of the Study:

• To investigate the anti-cancer effects of broussoflavonol B on ER-negative breast cancer stem-like cells.
• To compare the efficacy of broussoflavonol B with tamoxifen in inhibiting cancer stem-like cell growth and inducing differentiation.
• To explore the molecular targets of broussoflavonol B in breast cancer cells.

Main Methods:

• In vitro cell culture of SK-BR-3 cells, a model for ER-negative breast cancer.
• Treatment with broussoflavonol B and tamoxifen at sub-micromolar concentrations.
• Assessment of cell growth inhibition and differentiation induction.
• Analysis of Human epidermal growth factor receptor-2 (HER2) and ER-α36 protein levels via Western blotting or similar techniques.

Main Results:

• Broussoflavonol B demonstrated potent growth inhibitory activity against ER-negative breast cancer SK-BR-3 cells.
• Broussoflavonol B was more effective than tamoxifen in inhibiting growth and inducing differentiation of stem-like SK-BR-3 cells.
• Treatment with broussoflavonol B led to reduced levels of HER2 and ER-α36.

Conclusions:

• Broussoflavonol B is a potent inhibitor of ER-negative breast cancer stem-like cells.
• Broussoflavonol B exhibits therapeutic potential by targeting key pathways involved in breast cancer stemness and proliferation.
• Further pre-clinical and clinical evaluation of broussoflavonol B is warranted for breast cancer therapy.